| __timestamp | BioMarin Pharmaceutical Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 14400000 |
| Thursday, January 1, 2015 | 152008000 | 33800000 |
| Friday, January 1, 2016 | 209620000 | 35900000 |
| Sunday, January 1, 2017 | 241786000 | 1254000 |
| Monday, January 1, 2018 | 315264000 | 4889000 |
| Tuesday, January 1, 2019 | 359466000 | 7400000 |
| Wednesday, January 1, 2020 | 524272000 | 10100000 |
| Friday, January 1, 2021 | 470515000 | 14300000 |
| Saturday, January 1, 2022 | 483669000 | 23200000 |
| Sunday, January 1, 2023 | 577065000 | 39700000 |
| Monday, January 1, 2024 | 580235000 | 34000000 |
Data in motion
In the competitive landscape of biotechnology, understanding cost dynamics is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Neurocrine Biosciences, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, BioMarin's cost of revenue surged by approximately 345%, reflecting its aggressive expansion and increased production capabilities. In contrast, Neurocrine Biosciences experienced a more modest increase of around 176%, indicating a more controlled growth strategy.
These trends underscore the diverse strategies employed by biotech firms in managing operational costs, offering valuable insights for investors and industry analysts alike.
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored